Dr. Hensing on the Management of Stage III NSCLC

Thomas A. Hensing, MD
Published: Tuesday, Oct 03, 2017



Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Hensing says that in order to avoid the one-size-fits-all approach that has plagued stage IV disease management, new technology and novel therapeutics need to be adopted.

One of these technologies is proton-beam radiotherapy, but the problem is that it is expensive and there is limited access for patients, says Hensing.
 
SELECTED
LANGUAGE


Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).

Hensing says that in order to avoid the one-size-fits-all approach that has plagued stage IV disease management, new technology and novel therapeutics need to be adopted.

One of these technologies is proton-beam radiotherapy, but the problem is that it is expensive and there is limited access for patients, says Hensing.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x